p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy

Table 1 Clinicopathological characteristics and univariate analysis of ability to predict failure of tamoxifen therapy

^a9/60 indicates that there were 9 treatment failures out of 60 patients with known values for the indicated clinical characteristic. ^bThe percentage of treatment failures for the indicated clinical characteristic. ^c P is given for log-rank (or log-rank trend) univariate analysis. Sensitivity tests conducted with missing values provided no evidence for selection bias. ^dClinical characteristic was not determined. ^eFor patients with AJCC stage 2a and 3a disease and patients less than 50 years old, the RFS is reported at 7 years. For patients with tumor stage 3 disease, the RFS is reported at 6 years. AJCC, American Joint Committee on Cancer; PR, progesterone receptor; RFS, relapse-free survival.

ISSN: 1465-542X